JP2005068010A5 - - Google Patents

Download PDF

Info

Publication number
JP2005068010A5
JP2005068010A5 JP2003063378A JP2003063378A JP2005068010A5 JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5 JP 2003063378 A JP2003063378 A JP 2003063378A JP 2003063378 A JP2003063378 A JP 2003063378A JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5
Authority
JP
Japan
Prior art keywords
risedronate
pharmaceutical composition
unit dose
composition according
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003063378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005068010A (ja
Filing date
Publication date
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed filed Critical
Publication of JP2005068010A publication Critical patent/JP2005068010A/ja
Publication of JP2005068010A5 publication Critical patent/JP2005068010A5/ja
Pending legal-status Critical Current

Links

JP2003063378A 1997-07-22 2003-03-10 骨吸収を抑制する方法 Pending JP2005068010A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50991499A Division JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Publications (2)

Publication Number Publication Date
JP2005068010A JP2005068010A (ja) 2005-03-17
JP2005068010A5 true JP2005068010A5 (https=) 2005-06-16

Family

ID=27451690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法
JP2003063378A Pending JP2005068010A (ja) 1997-07-22 2003-03-10 骨吸収を抑制する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Country Status (31)

Country Link
EP (5) EP1175903A3 (https=)
JP (2) JP3479780B2 (https=)
KR (3) KR100391732B1 (https=)
CN (3) CN1166365C (https=)
AT (2) ATE209037T1 (https=)
AU (1) AU8493698A (https=)
BG (1) BG66282B1 (https=)
BR (1) BR9810779A (https=)
CA (1) CA2294595C (https=)
CY (2) CY1107535T1 (https=)
DE (6) DE01201911T1 (https=)
DK (2) DK1175904T3 (https=)
EA (1) EA004544B2 (https=)
EE (1) EE05603B1 (https=)
ES (3) ES2164447T3 (https=)
HK (4) HK1042230A1 (https=)
ID (1) ID24096A (https=)
IL (1) IL133535A0 (https=)
IS (3) IS5315A (https=)
LU (2) LU91222I2 (https=)
NL (2) NL300223I1 (https=)
NO (1) NO20000323L (https=)
NZ (1) NZ501807A (https=)
PL (1) PL195272B1 (https=)
PT (2) PT1175904E (https=)
SG (2) SG139556A1 (https=)
SI (1) SI0998292T1 (https=)
SK (1) SK932000A3 (https=)
TR (1) TR200000145T2 (https=)
UY (1) UY25950A1 (https=)
WO (1) WO1999004773A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038694A1 (en) 1998-12-25 2000-07-06 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
AU2001251432A1 (en) * 2000-04-07 2001-10-23 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
WO2007031785A2 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
CA2820019A1 (en) * 2010-12-06 2012-06-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
WO1997044017A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Effervescent bisphosphonate formulation

Similar Documents

Publication Publication Date Title
JP2005068010A5 (https=)
ES2247123T3 (es) Metodo para administrar bisfosfonatos.
HRP20130057T1 (hr) Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom
JP2013121983A5 (https=)
CA2434484A1 (en) Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2002509888A5 (https=)
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
JP2013231087A5 (https=)
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
JPH10147529A5 (https=)
JP2005519936A5 (https=)
JP2002540148A5 (https=)
RU2005105691A (ru) Пероральное введение кальцитонина
MXPA04004907A (es) Composiciones de acetaminofen.
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物